Answers are grounded in this paper and cite their sources.
Background: Gastric cancer is a widespread cancer and one of the leading causes of cancer death worldwide. In metastatic patients with HER2 overexpression the addition of Trastuzumab to first line chemotherapy improves tumor response and chance for survival. The optimal duration of Trastuzumab in this setting still unknown as well as the benefit of Trastuzumab continuation beyond progression in advanced gastric cancer.
No takes yet. Share an insight, caveat, or question.
Tanz et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: